Swiss startup creates modular device for on-demand cell therapy manufacturing
Switzerland-based Limula today announced a raise of $6.8mn (€6.2mn) to further develop its technology, which aims to automate cell therapy manufacturing. Gene and cell therapies have emerged as a promising treatment for life-threatening or difficult-to-manage diseases such as cancer, Parkinson’s, and Alzheimer’s. Such therapies place healthy genes and cells into the body to repair or replace malfunctioning on damaged ones. But despite their potential benefits, the high cost (up to $4.25mn) of these treatments comes with major accessibility barriers. Founded in 2020 by Dr Yann Pierson, Dr Luc Henry, and Dr Thomas Eaton, the Swiss startup seeks to replace outdated…This story continues at The Next Web
Switzerland-based Limula today announced a raise of $6.8mn (€6.2mn) to further develop its technology, which aims to automate cell therapy manufacturing. Gene and cell therapies have emerged as a promising treatment for life-threatening or difficult-to-manage diseases such as cancer, Parkinson’s, and Alzheimer’s. Such therapies place healthy genes and cells into the body to repair or replace malfunctioning on damaged ones. But despite their potential benefits, the high cost (up to $4.25mn) of these treatments comes with major accessibility barriers. Founded in 2020 by Dr Yann Pierson, Dr Luc Henry, and Dr Thomas Eaton, the Swiss startup seeks to replace outdated…
This story continues at The Next Web